Results 61 to 70 of about 28,422 (269)

Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. [PDF]

, 2015
BACKGROUND: Omalizumab is approved in the UK as add-on treatment for chronic spontaneous urticaria (CSU) in patients with inadequate response to H1-antihistamines. Ciclosporin is an established but unlicensed 3rd line option for CSU.
Ardern-Jones, MR, Baldock, L, Grattan, C, Leslie, T, Marsland, A, McKay, D, Savic, S, Somenzi, O   +7 more
core   +2 more sources

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

Omalizumab in allergic bronchopulmonary aspergillosis (ABPA): A systematic review and meta-analysis.

Journal of Allergy and Clinical Immunology: In Practice, 2022
BACKGROUND An unmet clinical need exists in the management of treatment-refractory allergic bronchopulmonary aspergillosis (ABPA). Omalizumab has shown promising effects in case series and cohort studies; however, evidence to support its routine clinical
Meiling Jin, J. Douglass, J. Elborn, R. Agarwal, W. Calhoun, S. Lazarewicz, X. Jaumont, Meng Yan   +7 more
semanticscholar   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Bullöses Wells‐Syndrom erfolgreich mit Omalizumab behandelt [PDF]

J Dtsch Dermatol Ges
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 5, Page 657-659, May 2026.
Ciccarese G, Rosato W, Drago F, Meduri A, Ambrogio F, De Marco A, Cazzato G, Foti C.   +7 more
europepmc   +2 more sources

Comparative Effectiveness of Dupilumab and Omalizumab on Asthma Exacerbations and Systemic Corticosteroid Prescriptions: Real-World US ADVANTAGE Study.

Journal of Allergy and Clinical Immunology
BACKGROUND In the US, dupilumab is approved for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma, while omalizumab is approved for managing moderate-to-severe allergic asthma uncontrolled by inhaled corticosteroids.
E. Bleecker, M. Blaiss, J. Jacob-Nara, L. Huynh, M. Duh, Tracy Guo, M. Ye, R. Stanford, Zhixiao Wang, X. Soler, Arpita Nag, Radhika Nair, K. Borsos   +12 more
semanticscholar   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis

Frontiers in Medicine
Hair loss is a rare adverse reaction associated with omalizumab, with limited literature reports. The incidence, underlying mechanisms, and clinical characteristics of omalizumab-associated hair loss have not been clarified.
Qian Wang, Hua Lei, Ge Yang, Ying Li, Wei Liu, Lixia Zhang, Xiyuan Zhou   +6 more
doaj   +1 more source

Appropriate selection for omalizumab treatment in patients with severe asthma?

European Clinical Respiratory Journal, 2017
Background: Omalizumab improves asthma control in patients with uncontrolled severe allergic asthma; however, appropriate patient selection is crucial. Information in this field is sparse.
Leo Nygaard, Daniel Pilsgaard Henriksen, Hanne Madsen, Jesper Rømhild Davidsen   +3 more
doaj   +1 more source

Astma ning selle ravi omalizumabiga: toime, ohutus ja kasutamine lastel [PDF]

, 2017
Bronhiaalastma on maailmas üks levinumaid haigusi, millele endiselt otsitakse tõhusamaid ravimeid. Kliinilises praktikas üle kümne aasta kasutatud immunoglobuliin E vastase monokloonse antikeha omalizumabi toime põhimõte on teada, kuid vaja on täpsustada,
Lääts, Liis
core   +2 more sources